Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe District, Shenyang, 110016, China; Ningxia Kangya Pharmaceutical Co., Ltd., Yinchuan, 750000, China.
Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe District, Shenyang, 110016, China.
Eur J Med Chem. 2022 Apr 15;234:114254. doi: 10.1016/j.ejmech.2022.114254. Epub 2022 Mar 9.
Three series of celastrol derivatives, namely, 6a-6i, 11a-11i and 15a-15i, were designed based on the scaffold hopping strategy. The derivatives were synthesized and biologically evaluated against five human tumor cell lines (i.e. A549, MCF-7, Bel7402, HT-29 and PC3) using MTT assay in vitro. Results showed that compound 11i exhibited apparent antiproliferative activity against the MCF-7 cell line with an IC value of 1.31 μM and could remarkably inhibit the colony formation of the MCF-7 cells. Transmission electron microscopy assay, monodansylcadaverine incorporation assay and the expression of LC3 A/B, p62 and Beclin-1 in MCF-7 cells suggested that the potent antiproliferative activity of compound 11i was mainly due to its autophagy-inducing effect. Moreover, compound 11i could arrest the MCF-7 cells in the G2/M phase by regulating the cell-cycle-related proteins Cdk-1 and Cyclin B1. In the zebrafish xenograft model, compound 11i could obviously inhibit the proliferation of the MCF-7 cells. Thus, compound 11i could serve as a promising lead compound for breast cancer therapy.
基于构象跳跃策略,设计了三个 celastrol 衍生物系列,即 6a-6i、11a-11i 和 15a-15i。通过 MTT 法在体外对五种人肿瘤细胞系(A549、MCF-7、Bel7402、HT-29 和 PC3)进行了合成和生物评价。结果表明,化合物 11i 对 MCF-7 细胞系表现出明显的增殖抑制活性,IC 值为 1.31μM,可显著抑制 MCF-7 细胞的集落形成。透射电子显微镜检测、单丹磺酰尸胺掺入试验以及 MCF-7 细胞中 LC3A/B、p62 和 Beclin-1 的表达表明,化合物 11i 的强增殖抑制活性主要归因于其自噬诱导作用。此外,化合物 11i 可以通过调节细胞周期相关蛋白 Cdk-1 和 Cyclin B1 将 MCF-7 细胞阻滞在 G2/M 期。在斑马鱼异种移植模型中,化合物 11i 可明显抑制 MCF-7 细胞的增殖。因此,化合物 11i 可以作为治疗乳腺癌的有前途的先导化合物。